TLSA
Tiziana Life Sciences Ltd
NASDAQ · Healthcare · Biotechnology · GB
$1.01
+3.64%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
Market Cap
$128.53M
MomentumView details →
1D Return
+3.64%
YTD Return
−32.21%
RSI (14)
46.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
Market Cap
$128.53M
RSI (14)
46.3
MomentumView details →
1D Return
+3.64%
YTD Return
−32.21%
SummaryUpdated Dec 1, 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a biotechnology company founded in 1998 and headquartered in London, United Kingdom. The company went public on November 20, 2018, and focuses on discovering and developing therapeutic molecules to treat human diseases in oncology and immunology. As a clinical-stage biotechnology firm, Tiziana operates without generating revenue from product sales, instead relying on research and development activities to advance its pipeline of experimental treatments through various stages of clinical trials.
Similar companies
Latest newsMore news →
Tiziana Life Sciences announced it will present Phase 2a BANYAN trial data for intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday.11d agoTiziana Life Sciences announced promising quantitative PET imaging results from the third patient in its Phase 2 clinical trial for a rare neurodegenerative condition, showing reduced neuroinflammation.35d agoTiziana Life Sciences dosed the last patient in its Phase 2a clinical trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis.71d ago